Abivax (ABVX) Operating Expenses (2022 - 2026)

Abivax's Operating Expenses history runs 5 years deep, the most recent figure standing at -$67.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 32.96% year-over-year to -$67.4 million in Q1 2026; TTM through Mar 2026 was $281.5 million, a 44.68% increase from a year earlier, with the FY2025 full-year figure at $291.7 million, up 45.36% from the prior year.
• Operating Expenses eased to -$67.4 million in Q1 2026 per ABVX's latest filing, from $499.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $499.6 million in Q4 2025 and bottomed at -$96.7 million in Q3 2025.
• The 5-year median for Operating Expenses is -$49.8 million (2024), against an average of $38.8 million.
• Across the five-year window, Operating Expenses tumbled 90.86% in 2023 and surged 256009642.09% in 2024, its largest moves.
• Year by year, Operating Expenses stood at -$70.81 in 2022, then tumbled by 90.86% to -$135.14 in 2023, then soared by 256009642.09% to $346.0 million in 2024, then surged by 44.4% to $499.6 million in 2025, then slumped by 113.49% to -$67.4 million in 2026.
• Per Business Quant, the three latest ABVX Operating Expenses figures stand at -$67.4 million (Q1 2026), $499.6 million (Q4 2025), and -$96.7 million (Q3 2025).